Disease manifestation and inflammatory activity as modulators of Th17/Treg balance and RORC/FoxP3 methylation in systemic sclerosis

International Archives of Allergy and Immunology

Volumn 171, Issue 2, 2016, Pages 141-154

  Almanzar, Giovanni ^a   Klein, Matthias ^a   Schmalzing, Marc ^a   Hilligardt, Deborah ^a   El Hajj, Nady ^a   Kneitz, Hermann ^a   Wild, Vanessa ^a   Rosenwald, Andreas ^a   Benoit, Sandrine ^a   Hamm, Henning ^a   Tony, Hans Peter ^a   Haaf, Thomas ^a   Goebeler, Matthias ^a   Prelog, Martina ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Methylation; Suppression; Systemic sclerosis; Th17; Tregs

Indexed keywords

AZATHIOPRINE; CHEMOKINE RECEPTOR CCR6; CYCLOPHOSPHAMIDE; INTERLEUKIN 17; METHOTREXATE; PREDNISONE; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; MEMBRANE ANTIGEN; RORC PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL FUNCTION; CELL PLASTICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; LIMITED CUTANEOUS SYSTEMIC SCLEROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN METHYLATION; REGULATORY T LYMPHOCYTE; SCLERODERMA; SYSTEMIC SCLEROSIS; TH17 CELL; TRANSCRIPTION INITIATION; DNA METHYLATION; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; METABOLISM; METHYLATION; SCLERODERMA, SYSTEMIC;

ADULT; AGED; ANTIGENS, SURFACE; BIOMARKERS; CYTOKINES; DNA METHYLATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOPENIA; MALE; METHYLATION; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 85001094002     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000450949     Document Type: Article

References (57)

1. Baraut J, Michel L, Verrecchia F, Farge D: Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010; 10: 65-73
2. Kurzinski K, Torok KS: Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine 2011; 55: 157-164
3. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al: Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-2463
4. Murata M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, et al: Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008; 50: 240-242
5. Radstake TR, Van Bon L, Broen J, Hussiani A, Hesselstrand R, Wuttge DM, et al: The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFβ and IFN? distinguishes SSc phenotypes. PLoS One 2009; 4: e5903
6. Deleuran B, Abraham DJ: Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 2007; 3: 682-683
7. Rodriguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, Fajardo-Hermosillo LD, Martinez- Reyes C, Diaz-Zamudio M, et al: Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 2012; 32: 2653-2660
8. Mathian A, Parizot C, Dorgham K, Trad S, Arnaud L, Larsen M, et al: Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 2012; 71: 1227-1234
9. Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, et al: Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 2010; 162: 1056-1063
10. Levings MK, Bacchetta R, Schulz U, Roncarolo MG: The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 129: 263-276
11. Veldman C, Nagel A, Hertl M: Type I regulatory T cells in autoimmunity and inflammatory diseases. Int Arch Allergy Immunol 2006; 140: 174-183
12. Klein S, Kretz CC, Ruland V, Stumpf C, Haust M, Hartschuh W, et al: Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 2011; 70: 1475-1481
13. Radstake TR, Van Bon L, Broen J, Wenink M, Santegoets K, Deng Y, et al: Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression. PLoS One 2009; 4: e5981
14. Slobodin G, Ahmad MS, Rosner I, Peri R, Rozenbaum M, Kessel A, et al: Regulatory T cells (CD4 + CD25 bright FoxP3 + ) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 2010; 261: 77-80
15. Giovannetti A, Rosato E, Renzi C, Maselli A, Gambardella L, Giammarioli AM, et al: Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol 2010; 137: 122-133
16. Yang X, Yang J, Xing X, Wan L, Li M: Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther 2014; 16: R4
17. Zhou Y, Hou W, Xu K, Han D, Jiang C, Mou K, et al: The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis. Hum Immunol 2015; 76: 22-29
18. Liu M, Wu W, Sun X, Yang J, Xu J, Fu W, Li M: New insights into CD4+ T cell abnormalities in systemic sclerosis. Cytokine Growth Factor Rev 2016; 28: 31-36
19. Yamamoto T: Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol 2006; 140: 345-356
20. Khoury SJ: Th17 and Treg balance in systemic sclerosis. Clin Immunol 2011; 139: 231-232
21. Lei W, Luo Y, Yan K, Zhao S, Li Y, Qiu X, et al: Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol 2009; 38: 369-374
22. Jiang H, Xiao R, Lian X, Kanekura T, Luo Y, Yin Y, et al: Demethylation of TNFSF7 contributes to CD70 overexpression in CD4+ T cells from patients with systemic sclerosis. Clin Immunol 2012; 143: 39-44
23. Selmi C, Feghali-Bostwick CA, Lleo A, Lombardi SA, De Santis M, Cavaciocchi E, et al: X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. Clin Exp Immunol 2012; 169: 253-262
24. Altorok N, Almeshal N, Wang Y, Kahaleh B: Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2015; 54: 1759-1770
25. Wang YY, Wang Q, Sun XH, Liu RZ, Shu Y, Kanekura T, et al: DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br J Dermatol 2014; 171: 39-47
26. Van den Hoogen KD, Fransen J, Johnson SR, Baron M, Tyndall A, et al: 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism Collaborative initiative. Ann Rheum Dis 2013; 72: 1747-1755
27. Muangchan C; Canadian Scleroderma Research Group, Baron M, Pope J: The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol 2013; 40: 1545-1556
28. Fenoglio D, Battaglia F, Parodi A, Stringara S, Negrini S, Panico N, et al: Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 2011; 139: 249-257
29. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, et al: Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008; 205: 1903-1916
30. Brembilla NC, Montanari E, Truchetet ME, Raschi E, Meroni P, Chizzolini C: Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther 2013; 15: R151
31. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F: Production of interleukin 22 but not interleukin 17 by a subset of human skinhoming memory T cells. Nat Immunol 2009; 10: 857-863
32. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H: Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009; 10: 864-871
33. Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C: Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 2011; 13: R166
34. Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM: Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 2008; 180: 214-221
35. Ochoa E, Martin JE, Assasi S, Beretta L, Carreira P, Guillen A, et al: Confirmation of CCR6 as a risk factor for anti-Topoisomerase I antibodies in systemic sclerosis. Clin Exp Rheumatol 2015; 33: S31-S35
36. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al: Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009; 11: R147
37. Peltonen J, Kahari L, Jaakkola S, Kahari VM, Varga J, Uitto J, et al: Evaluation of transforming growth factor beta and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J Invest Dermatol 1990; 94: 365-371
38. Warrington KJ, Nair U, Carbone LD, Kang AH, Postlethwaite AE: Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther 2006; 8: R136
39. Sato S, Hasegawa M, Takehara K: Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001; 27: 140-146
40. Kucharz EJ, Brzezinska-Wcislo L, Kotulska A, Gasiorowska-Kielkowska W, Gozdzik J: Elevated serum level of interleukin-10 in patients with systemic sclerosis. Clin Rheumatol 1997; 16: 638-639
41. Mathes AL, Christmann RB, Stifano G, Affandi AJ, Radstake TR, Farina GA, et al: Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin. Ann Rheum Dis 2014; 73: 1864-1872
42. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al: Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911
43. Papp G, Horvath IF, Barath S, Gyimesi E, Sipka S, Szodoray P, et al: Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 2011; 40: 205-210
44. Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, et al: DC activated via dectin-1 convert Treg into IL-17 producers. Eur J Immunol 2008; 38: 3274-3281
45. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, et al: Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29: 44-56
46. Koenen HJ, Smeets RL, Vink PM, Van Rijssen E, Boots AM, Joosten I: Human CD-25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340-2352
47. Lim HW, Lee J, Hillsamer P, Kim CH: Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J Immunol 2008; 180: 122-129
48. Klein S, Kretz CC, Krammer PH, Kuhn A: CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. J Invest Dermatol 2010; 130: 492-499
49. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA: Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009; 21: 281-285
50. Bovenschen HJ, Van De Kerkhof PC, Van Erp PE, Woestenenk R, Joosten I, Koenen HJ: Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 2011; 131: 1853-1860
51. Braitch M, Harikrishnan S, Robins RA, Nichols C, Fahey AJ, Showe L, et al: Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis. Acta Neurol Scand 2009; 119: 239-245
52. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM: Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006; 36: 2139-2149
53. Olewicz-Gawlik A, Danczak-Pazdrowska A, Kuznar-Kaminska B, Gornowicz-Porowska J, Katulska K, Trzybulska D, et al: Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Int J Rheum Dis 2014; 17: 664-670
54. Yan JW, Wang YJ, Peng WJ, Tao JH, Wan YN, Li BZ, et al: Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases. Expert Opin Ther Targets 2014; 18: 29-41
55. Kumar P, Subramaniyam G: Molecular underpinnings of Th17 immune-regulation and their implications in autoimmune diabetes. Cytokine 2015; 17: 366-376
56. Liu H, Cao AT, Feng T, Li Q, Zhang W, Yao S, et al: TGF-β converts Th1 cells into Th17 cells through stimulation of Runx1 expression. Eur J Immunol 2015; 45: 1010-1018
57. Mazzoni A, Santerlasci V, Maggi L, Capone M, Rossi MC, Querci V, et al: Demethylation of the RORC2 and IL17A in human CD4+ T lymphocytes defines Th17 origin of nonclassic Th1 cells. J Immunol 2015; 194: 3116-3126